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EDITORIAL
Qualiﬁed Promise: DNA Methylation Assays for the
Detection and Classiﬁcation of Human Cancers
Wolfgang Schulz
Department of Urology, Heinrich Heine University, Moorenstrasse 5, Duesseldorf 40225, Germany
In the last decade, epigenetic changes have been rec-
ognized as important factors in the development and
progression of human cancers. Speciﬁcally, alterations of
DNA methylation patterns are now thought to contribute
to altered gene expression and chromosomal instability,
to an often comparable degree as genetic alterations such
as point mutations, insertions, deletions, chromosomal
translocations, gains, and losses.
Of note, DNA methylation patterns in cancer cells can
change in both directions, that is, decreases as well as in-
creases are found. Decreased methylation (“hypomethy-
lation”) and increased methylation (“hypermethylation”)
can occur independently of each other, but also simul-
taneously. While some methylation changes are subtle,
two stand out as clearly pathological. The sequences sur-
rounding the transcriptional start sites of many genes are
particularly rich in the dinucleotide CpG compared to
the rest of the genome. Many of these sequences, termed
“CpG-islands,” are normally devoid of DNA methylation.
Therefore, hypermethylation of such CpG-islands is evi-
dently an aberrant process that is largely restricted to can-
cers. Limited and “patchy” CpG-island hypermethylation
is observed in preneoplastic and aging tissues, while in
some cancers, hundreds of CpG-islands become densely
hypermethylated. Conversely, some sequences that are
densely methylated in somatic cells become hypomethy-
lated. In normal somatic cells, the CpG-rich satellite se-
quences SAT2 and SAT3 and interspersed CpG-rich retro-
transposons like LINE-1 and ALU are strongly methy-
lated. As these repeat sequences constitute the bulk of
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the genome and become hypomethylated in many can-
cers, hypomethylation is typically the dominant alter-
ation. Methylation of repeat sequences decreases in many
cancersinaseeminglyunspeciﬁcfashion,buthypomethy-
lation also aﬀects a number of single-copy genes. Im-
portantly, neither hypomethylation of single-copy genes
nor hypermethylation of CpG-islands seem to occur in
a random manner and show considerable diﬀerences be-
tween cancer types and subtypes. The hypermethylation
of a CpG-island or the hypomethylation of a gene pro-
moter that is methylated in normal somatic tissue there-
fore strongly hints at a functional importance in each
individual case. Accordingly, hypermethylation of CpG-
island promoters is a common mechanism for inactiva-
tion oftumorsuppressorgenesincancerandhypomethy-
lation of certain genes may be required to equip tumor
cells with proteins necessary for invasion and metasta-
sis. On a note of caution, though, it is rather unlikely
that every instance of altered gene methylation implies
important functional signiﬁcances. For instance, tumor
cells may beneﬁt from “slimming down” gene expression
by hypermethylation of “unnecessary” genes, but their
growth may not depend on this change.
Apart from its functional signiﬁcance, altered DNA
methylation in cancer has attracted great attention as a
tool for cancer diagnosis. A large variety of techniques
are now available to determine DNA methylation of the
genome at large, of speciﬁc sites in speciﬁc genes, of
speciﬁc regions, or of multiple genes. They comprise
“classical” blotting techniques relying on methylation-
sensitive restriction enzymes, a host of PCR techniques,
usually following bisulﬁte treatment of DNA which con-
verts only unmethylated cytosines to uracil, HPLC-based
methodology, several variants of mass spectometry, aﬃn-
ity chromatography using, for example, methylcytosine
binding proteins, andvarious arraytechniques.Twoobvi-
ous trends in the application of methylation methodology
are an emphasis on improved quantiﬁcation, exempliﬁed
by the use of quantitative (real-time) PCR techniques,
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multiplex PCR, arrays, or mass spectometry-based tech-
niques. For the time being, the “gold standard” for the
determination of methylation patterns remains bisulﬁte
sequencing which allows a precise determination of each
CpG site within a few hundred base pairs on individual
alleles, but mass spectrometry techniques are catching up.
Eachofthesemethodsisusefulforthepurposeofcan-
cer diagnosis in one or the other case. Principally, two dif-
ferent aims can be pursued by DNA methylation assays:
cancer detection and cancer classiﬁcation. Each aim im-
plies diﬀerent requirements, as discussed below, but both
beneﬁt from certain properties of DNA and DNA methy-
lation.DNAisamorestablemoleculethanRNAandmost
proteins, facilitating sampling in a clinical routine set-
ting. Similarly, DNA methylation patterns do not change
rapidly in vivo (they usually require one or two com-
plete cell cycles to be reset) and remain stable in isolated
DNA (the 5-position of cytosine is among the least reac-
tiveones,unlessactivatedbymethyltransferases).Perhaps
most importantly, some sites in DNA are never methy-
lated in normal cells, for example, many of those located
inCpG-islands.Therefore,determinationofhypermethy-
lation, in particular, can often be performed against a true
zero background. Hypomethylation detection is more te-
dious, since methylation of a single site may exceed 99%
(ie, the site is methylated in 99 out of 100 alleles), but
does not usually reach 100% (ie, a speciﬁc site remains
unmethylated on an occasional allele). This yields a the-
oretical and practical limit, but combining several sites of
thiskindstillcanyieldextraordinarilyhighspeciﬁcityand
sensitivity.
Nevertheless, as a rule, hypermethylation assays seem
to constitute the method of choice for cancer detection.
Because of the low background methylation in normal
cells, the sensitivity of hypermethylation assays is usually
not limited by the technique used, but by the biological
propertiesofthecancerinquestion.Ideally,oneorseveral
genes would be consistently hypermethylated in a certain
cancer type, but such cases are rare. Prostate cancer may
be singularin thathalf a dozen genes including GSTP1are
coordinately hypermethylated at an early stage of its de-
velopment in more than 80% of all cases. Thus, between
85% and 95% of all prostate cancers may be detectable
by a small panel of hypermethylation assays. Use of sev-
eral genes for detection is advisable not only because it
increases the sensitivity of the assay, but also because it
is more robust and discriminates better against methyla-
tion changes in preneoplastic or aging tissues. Unfortu-
nately, in most other cancer types, no single gene is hy-
permethylated in such a large fraction of the cases and
even combinations of methylation markers do not detect
all. Some cancers, such as common type renal cell carci-
noma, present very few methylation changes, especially
when compared to aging tissues. The biological basis of
these diﬀerences is obviously extremely interesting, but
not understood. It has been postulated that some tumors
exhibit a “methylator phenotype” which leads to hyper-
methylation as the preferred mode of tumor suppressor
inactivation (compared to deletion and point mutation).
Others have suggested that there is rather a gradual range
of tumors with some exhibiting very few and others many
methylationchanges.Atanyrate,theprospectsfortheuse
of methylation assays for detection appear to vary consid-
erably for diﬀerent cancer types.
Another important consideration concerns the choice
of samples for cancer detection. Investigating biopsies
from a presumed cancerous tissue may be hampered by
sampling error only. Similarly, detecting lung cancer in
sputum or bladder cancer in urine by investigating the
DNA of cells shed into the lumen is likely to be reliable. A
diﬀerent issue is detection of altered methylation in DNA
from blood, a sort of assay usually performed with cell-
free DNA present in plasma. This type of detection may
be biased towards detection of advanced tumors in close
contact with the vasculature and may in fact represent
a sort of “molecular staging.” With this consideration in
mind, of course, detection of cells with aberrantly methy-
lated DNA in lymph nodes or bone marrow may turn out
to be highly useful in the clinic.
Inasense,thislatterapplicationtranscendstheborder
into cancer classiﬁcation. In general, classiﬁcation of can-
cers by DNA methylation analysis is applicable for several
purposes, including the distinction between histological
subtypes, between cancers of diﬀerent stages (see above)
or grades, between morphologically similar cancers with
diﬀerent prognoses, and between cancers responding dif-
ferently to diﬀerent treatments. It is commonly assumed
that making such distinctions will require the analysis of
multiple methylation sites in multiple genes. Most likely,
assays for this purpose will comprise hypomethylation as
well as hypermethylation analyses, because increasing hy-
pomethylation is often a feature of more aggressive can-
c e r s .M o r e o v e r ,a sm a n ys i t e sw i l lh a v et ob es a m p l e d ,
techniques suitable for high-throughput or automation
are expected to be employed. Obviously, cancer classi-
ﬁcation by methylation analysis will be a considerable
more diﬃcult task than cancer detection. One foreseeable
complication, already experienced in expression proﬁling
studies, is that the classiﬁcations of human cancers sug-
gested by molecular markers may follow established di-
vision lines in some cases, but may well run contrary to
them in others. This may be particularly so with methy-
lation analyses because methylation changes drive cancer
developmenttodiﬀerentdegreesinindividualcasesofthe
same cancer type. For instance, individual colon cancers
diﬀer so substantially in the extent of methylation alter-
ationsthatasubgroupwitha“methylatorphenotype”has
been postulated.
Therefore,intheshortrun,themostlikelyapplication
for classiﬁcation based on methylation analysis might be
the molecular distinction between histological types in
the same organ (e.g., diﬀerent lung or testicular cancers),
because the diﬀerences in methylation are rather clear-cut
and in accordance with established histological subtyp-
ing. A second application likely to enter clinical practice
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pursued actively and jointly by academic groups and
industry. Speciﬁcally, hypermethylation of DNA repair,
apoptosis, and checkpoint genes may presage the success
of “classical” cytotoxic chemotherapy, but perhaps even
the eﬃcacy of “novel” targeted drugs in individual pa-
tients.
Finally, a prerequisite to make the promise of DNA
methylation assays come true as they move from research
labs into the clinic is improved standardization and qual-
ity control. A few examples may serve to indicate the scale
of the problem. One report indicated a 100% sensitivity
and speciﬁcity for detection of renal cancers by methyla-
tion analysis from urine, whereas in others hypermethy-
lation was only observed in a fraction of primary renal
cancer tissues. Another paper reported 100% hyperme-
thylation of the p14 promoter in the CDKN2A gene in a
cancer type where at least 20% of the cases carry homozy-
gous deletions of the gene. Even the reported frequen-
cies of a basically robust marker, like GSTP1 hyperme-
thylation in prostate cancer, vary between 36% and 99%
in diﬀerent reports. Obviously, standardization of DNA
methylation assays is anything but a trivial issue. Some
discrepancies may result from technicalities or exagger-
ated claims, but the very properties of DNA methylation
as a biological process may contribute. DNA methylation
patterns are rarely 100% identical between cells of one
type, even those of a clonal population, and they are dy-
namic. Thus, a densely hypermethylated CpG-island in a
cancercellmaycontainafewunmethylatedCpGsitesthat
vary between individual alleles. Moreover, hypermethy-
lation is not dense in each gene aﬀected in human can-
cers, so some of the variability found in the literature may
derive from this fact. Moreover, DNA methylation pat-
terns can change during the course of a cancer. The best
documented case concerns the CDH1 gene encoding E-
Cadherin. The gene is down-regulated and to varying ex-
tents hypermethylated when carcinoma cells undergo a
cadherin isotype switch associated with an invasive phe-
notype. Conversely, however, expression of the protein is
advantageousformetastasesoncetheyareestablished.Ac-
cordingly,methylationofthegenepromotermaydecrease
again in metastases. Given this dynamic behavior, the ir-
ritating diﬀerences in the frequencies of CDH1 hyperme-
thylation reported, for example, in prostate and bladder
cancer become more understandable.
In conclusion, DNA methylation assays hold great
promiseforthebetterdetectionandclassiﬁcationofmany
humancancers,evenifthelimitsoftheapproacharecriti-
callyconsidered.Manytechniquesareapplicable,depend-
ing on the purpose. Sensitivity, standardization, quality
control, and automation are being developed and will fa-
cilitate translation into the clinic. Importantly, to make
promise come true, the biological basis of DNA methy-
lation alterations needs to be thoroughly understood for
each human cancer type.
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